GlassScriptPhysician profile
Igor Khelemsky
NPI 1962431148
$7,639.53
in general payments reported to CMS, 2019-2025
33 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $831 · 2021: $994 · 2022: $1,672 · 2023: $1,857 · 2024: $1,328 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,826 · Education: $76.49 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,825.72 |
| Education | $76.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,501.50 | 2021-2025 | |
| Pfizer INC. | $1,114.83 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $660.14 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $610.40 | 2022 | |
| Novartis Pharmaceuticals Corporation | $522.86 | 2019-2025 | |
| Lilly USA, LLC | $469.76 | 2020-2024 | Emgality, Reyvow, Amyvid |
| Amgen INC. | $358.47 | 2019-2025 | Aimovig, Uplizna |
| Teva Pharmaceuticals USA, INC. | $331.73 | 2020-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Scilex Pharmaceuticals INC. | $316.72 | 2019-2025 | Ztlido |
| Celgene Corporation | $302.37 | 2023-2025 | Zeposia |
| Biogen, INC. | $192.97 | 2019-2024 | Tysabri, Vumerity, Leqembi |
| Amneal Pharmaceuticals LLC | $184.44 | 2019-2024 | Rytary |
| Neurocrine Biosciences, INC. | $127.04 | 2020-2023 | Ongentys, Ingrezza |
| Medtronic, INC. | $101.00 | 2023-2025 | Percept PC Brainsense, Intellis Adaptivestim |
| Lundbeck LLC | $90.52 | 2022-2023 | Vyepti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $89.42 | 2020-2022 | |
| Upsher-Smith Laboratories LLC | $67.96 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $67.65 | 2022 | |
| Endo Pharmaceuticals INC. | $60.35 | 2020 | |
| Mdd US Operations, LLC | $53.33 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $51.28 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $49.85 | 2023-2024 | Dysport |
| Genzyme Corporation | $41.39 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $39.33 | 2020 | |
| Eisai INC. | $36.26 | 2020 | |
| Neurelis, INC. | $34.44 | 2023 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $31.59 | 2023-2024 | |
| Axsome Therapeutics, INC. | $27.21 | 2023 | Auvelity |
| Harmony Biosciences LLC | $25.39 | 2020 | |
| Sk Life Science, INC. | $23.08 | 2020 | |
| Jazz Pharmaceuticals INC. | $22.76 | 2019 | |
| Avion Pharmaceuticals | $20.00 | 2023 | Dhivy |
| Ge Healthcare | $13.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Khelemsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.